Teneligliptin Explained

Teneligliptin (INN; trade name Tenelia) is a pharmaceutical drug for the treatment of type 2 diabetes mellitus. It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".^[1]

Creation

It was created by Mitsubishi Tanabe Pharma and launched in September 2012 by both Mitsubishi Tanabe Pharma and Daiichi Sankyo in Japan.^[2]

Licensing and use

Japan/Korea/India/Argentina

It is approved for use in Japan, Argentina, Korea and India.^[3]

Pharmacology

Teneligliptin has unique J-shaped or anchor locked domain structure because of which it has a potent inhibition of DPP 4 enzyme.

Teneligliptin significantly controls glycemic parameters with safety. No dose adjustment is required in renally impaired patients.^[4]

Notes and References

1. Kishimoto M . Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 6 . 187–195 . 2013 . 23671395 . 3650886 . 10.2147/DMSO.S35682 . free .
2. Web site: TENELIA® 20mg tablets, a Treatment for Type 2 Diabetes Mellitus Approval of Partial Change in Indication to Lift Restrictions in Combination Therapy . https://web.archive.org/web/20151124051120/http://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/006054.html . 24 November 2015 . 20 December 2013 . Media & Investors . Daiichi Sankyo .
3. Book: Annual Reports in Medicinal Chemistry . 48 . 523–524 . Teneligliptin (Antidiabetic), Chapter: To Market, To Market - 2012 . Bronson J, Black A, Dhar TG, Ellsworth BA, Merritt JR . 10.1016/b978-0-12-417150-3.00028-4. 2013 . 978-0-12-417150-3 .
4. Nabeno M, Akahoshi F, Kishida H, Miyaguchi I, Tanaka Y, Ishii S, Kadowaki T . A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site . Biochemical and Biophysical Research Communications . 434 . 2 . 191–196 . May 2013 . 23501107 . 10.1016/j.bbrc.2013.03.010 .